BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 169 filers reported holding BRIDGEBIO PHARMA INC in Q4 2020. The put-call ratio across all filers is 0.33 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,112,603 | +10.6% | 42,192 | -27.8% | 0.00% | 0.0% |
| Q2 2023 | $1,005,685 | +123296.9% | 58,470 | +18.8% | 0.00% | 0.0% |
| Q1 2023 | $815 | +136.2% | 49,202 | +8.6% | 0.00% | +100.0% |
| Q4 2022 | $345 | -99.9% | 45,317 | -10.0% | 0.00% | -33.3% |
| Q3 2022 | $500,000 | -17.5% | 50,363 | -24.7% | 0.00% | 0.0% |
| Q2 2022 | $606,000 | -33.8% | 66,839 | -26.0% | 0.00% | -25.0% |
| Q1 2022 | $915,000 | -95.1% | 90,288 | -91.9% | 0.00% | -95.3% |
| Q4 2021 | $18,500,000 | -52.8% | 1,109,233 | +32.5% | 0.09% | -58.3% |
| Q3 2021 | $39,224,000 | -22.7% | 836,914 | +0.6% | 0.21% | -28.0% |
| Q2 2021 | $50,722,000 | +0.5% | 832,084 | +1.5% | 0.29% | -16.4% |
| Q1 2021 | $50,488,000 | -8.6% | 819,632 | +5.5% | 0.34% | -18.2% |
| Q4 2020 | $55,253,000 | – | 777,031 | – | 0.42% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $100,609,513 | 48.41% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $514,990,899 | 15.50% |
| M28 Capital Management LP | 304,700 | $5,051,926 | 5.71% |
| Cormorant Asset Management, LP | 4,557,414 | $75,562 | 4.98% |
| Octagon Capital Advisors LP | 1,338,160 | $22,186,693 | 3.19% |
| Ikarian Capital, LLC | 594,686 | $9,859,894 | 2.24% |
| Affinity Asset Advisors, LLC | 389,800 | $6,462,884 | 2.13% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $441,376,031 | 2.07% |
| Ikarian Capital, LLC | 549,600 | $9,112,368 | 2.07% |
| Affinity Asset Advisors, LLC | 320,000 | $5,305,600 | 1.75% |